CLINICAL RESPONSE TO SUCCINYLCHOLINE: CLINICAL EXOME PANEL (Sec. & CNVs) – 2 genes
Delivery time
3-4 weeks
Sample
Blood
This panel is designed to detect genetic variants associated with serious adverse reactions during the administration of succinylcholine and other depolarizing muscle relaxants used in general anesthesia. It evaluates the CACNA1S and RYR1 genes, mutations in which are linked to susceptibility to malignant hyperthermia, a potentially fatal complication characterized by hypercapnia, muscle rigidity, tachycardia, and sudden hyperthermia following exposure to certain anesthetics or neuromuscular blocking agents. Identifying pathogenic variants allows for the prevention of this reaction through the selection of alternative anesthetic agents and the implementation of preoperative safety measures.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€